We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
- Authors
Al-Ejeh, Fares; Shi, Wei; Miranda, Mariska; Simpson, Peter T; Vargas, Ana Cristina; Song, Sarah; Wiegmans, Adrian P; Swarbrick, Alex; Welm, Alana L; Brown, Michael P; Chenevix-Trench, Georgia; Lakhani, Sunil R; Khanna, Kum Kum
- Abstract
Triple-negative breast cancer (TNBC) is associated with poor survival. Chemotherapy is the only standard treatment for TNBC. The prevalence of BRCA1 inactivation in TNBC has rationalized clinical trials of poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors. Similarly, the overexpression of epidermal growth factor receptor (EGFR) rationalized anti-EGFR therapies in this disease. However, clinical trials using these 2 strategies have not reached their promise. In this study, we used EGFR as a target for radioimmunotherapy and hypothesized that EGFR-directed radioimmunotherapy can deliver a continuous lethal radiation dose to residual tumors that are radiosensitized by PARP inhibitors and chemotherapy.
- Publication
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Vol 54, Issue 6, p913
- ISSN
1535-5667
- Publication type
Journal Article
- DOI
10.2967/jnumed.112.111534